These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19959959)

  • 1. Impulse control disorder and piribedil: report of 5 cases.
    Tschopp L; Salazar Z; Gomez Botello MT; Roca CU; Micheli F
    Clin Neuropharmacol; 2010; 33(1):11-3. PubMed ID: 19959959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse control disorders in Parkinson disease: a multicenter case--control study.
    Voon V; Sohr M; Lang AE; Potenza MN; Siderowf AD; Whetteckey J; Weintraub D; Wunderlich GR; Stacy M
    Ann Neurol; 2011 Jun; 69(6):986-96. PubMed ID: 21416496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease.
    Drapier D; Drapier S; Sauleau P; Derkinderen P; Damier P; Allain H; Vérin M; Millet B
    Psychiatry Res; 2006 Nov; 144(2-3):241-4. PubMed ID: 17011634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease.
    Fenu S; Wardas J; Morelli M
    Behav Pharmacol; 2009 Sep; 20(5-6):363-79. PubMed ID: 19724195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulse control disorders and dopaminergic treatments in Parkinson's disease.
    Villa C; Pascual-Sedano B; Pagonabarraga J; Kulisevsky J
    Rev Neurol (Paris); 2011 Nov; 167(11):827-32. PubMed ID: 21596410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impulse control disorders and punding in Parkinson's disease: the need for a structured interview.
    Ávila A; Cardona X; Bello J; Maho P; Sastre F; Martín-Baranera M
    Neurologia; 2011 Apr; 26(3):166-72. PubMed ID: 21163239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
    Simon N; Micallef J; Reynier JC; Lesourd M; Witjas T; Alicherif A; Azulay JP; Blin O
    Mov Disord; 2005 Jul; 20(7):803-9. PubMed ID: 15726579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piribedil and pathological gambling in six parkinsonian patients.
    Micheli FE; Giugni JC; Espinosa ME; Calvo DS; Raina GB
    Arq Neuropsiquiatr; 2015 Feb; 73(2):115-8. PubMed ID: 25742580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonists and therapy compliance.
    Grosset D
    Neurol Sci; 2008 Dec; 29 Suppl 5():S375-6. PubMed ID: 19381766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease.
    Potenza MN; Voon V; Weintraub D
    Nat Clin Pract Neurol; 2007 Dec; 3(12):664-72. PubMed ID: 18046439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impulsive and compulsive behaviors in Parkinson's disease: a one-year follow-up study.
    Ávila A; Cardona X; Martín-Baranera M; Bello J; Sastre F
    J Neurol Sci; 2011 Nov; 310(1-2):197-201. PubMed ID: 21683375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease.
    Perez-Lloret S; Rey MV; Fabre N; Ory F; Spampinato U; Brefel-Courbon C; Montastruc JL; Rascol O
    Clin Neuropharmacol; 2012; 35(6):261-5. PubMed ID: 23123689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is dopamine agonist therapy associated with developing pathological gambling in Parkinson's disease patients?
    Zand R
    Eur Neurol; 2008; 59(3-4):183-6. PubMed ID: 18230877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent impulse control disorders in piribedil overdose.
    Giugni JC; Tschopp L; Escalante V; Micheli F
    Clin Neuropharmacol; 2012; 35(1):49-50. PubMed ID: 22240861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impulse control disorders and Parkinson's disease].
    Burkhard PR; Catalano-Chiuvé S; Gronchi-Perrin A; Berney A; Vingerhoets FJ; Lüscher C
    Rev Med Suisse; 2008 May; 4(156):1145-8, 1150. PubMed ID: 18630168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field.
    Ambermoon P; Carter A; Hall WD; Dissanayaka NN; O'Sullivan JD
    Addiction; 2011 Feb; 106(2):283-93. PubMed ID: 21134016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.